Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Hematologic complications of malignancy: Anemia and bleeding

Reed E Drews, MD
Section Editor
Stanley L Schrier, MD
Deputy Editor
Jennifer S Tirnauer, MD


Anemia frequently complicates the course of cancer. While anemia may be a presenting sign of malignancy, it may also be a consequence of a patient's antineoplastic therapy or progressive disease. Since anemia is a frequent cause of fatigue and fatigue ranks as the most common symptom plaguing cancer patients and limiting their daily routines, recognizing anemia and its causes is important for identifying appropriate interventions that may improve the cancer patient's quality of life [1-5]. (See "Cancer-related fatigue: Prevalence, screening and clinical assessment", section on 'Anemia' and "Cancer-related fatigue: Treatment", section on 'Anemic patients'.)

This review will discuss those causes of anemia that are of specific relevance in patients with neoplastic disease. A general discussion of anemia and treatment of anemia in patients with malignancy is presented separately. (See "Approach to the adult patient with anemia" and "Anemias due to decreased red cell production" and "Diagnosis of hemolytic anemia in the adult" and "Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer".)


Mechanisms — As with anemias in general, three broad categories should be considered when assessing causes of anemia in patients with malignancies. (See "Approach to the adult patient with anemia", section on 'Causes of anemia'.)

Red blood cell (RBC) losses from the body (blood loss anemia)

Increased RBC destruction (hemolytic anemia)


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Sep 16, 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Vogelzang NJ, Breitbart W, Cella D, et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 1997; 34:4.
  2. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999; 91:1616.
  3. Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001; 19:2865.
  4. Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001; 19:2875.
  5. Seidenfeld J, Piper M, Flamm C, et al. Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 2001; 93:1204.
  6. Escobar MA. Bleeding in the patient with a malignancy: is it an acquired factor VIII inhibitor? Cancer 2012; 118:312.
  7. Macciò A, Madeddu C, Gramignano G, et al. The role of inflammation, iron, and nutritional status in cancer-related anemia: results of a large, prospective, observational study. Haematologica 2015; 100:124.
  8. McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev 2013; 39:534.
  9. Rodgers GM 3rd, Becker PS, Bennett CL, et al. Cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw 2008; 6:536.
  10. United States FDA toxicity criteria, search under "hemoglobim" at: www.fda.gov/cder/cancer/toxicityframe.htm (Accessed on July 21, 2008).
  11. Reid TJ 3rd, Stamm CP, Dunning DM, Redmond J 3rd. Iron malabsorption in a patient with large cell lymphoma involving the duodenum. Am J Gastroenterol 1992; 87:1478.
  12. Dauth J, de Coning JP, Politzer WM, et al. Unusual presentation of multiple myeloma. A report of 2 cases. S Afr Med J 1984; 65:968.
  13. Sutton DR, Baird IM, Stewart JS, et al. Gastrointestinal iron losses in atrophic gastritis, postgastrectomy states and adult coeliac disease. Gut 1971; 12:869.
  14. Kimber C, Patterson JF, Weintraub LR. The pathogenesis of iron deficiency anemia following partial gastrectomy. A study of iron balance. JAMA 1967; 202:935.
  15. Schade SG, Cohen RJ, Conrad ME. Effect of hydrochloric acid on iron absorption. N Engl J Med 1968; 279:672.
  16. Ekenved G. Iron absorption studies. Studies on oral iron preparations using serum iron and different radioiron isotope techniques. Scand J Haematol Suppl 1976; 28:1.
  17. Dewar GA, Griffin SM, Ku KW, et al. Management of bleeding liver tumours in Hong Kong. Br J Surg 1991; 78:463.
  18. Srivastava DN, Gandhi D, Julka PK, Tandon RK. Gastrointestinal hemorrhage in hepatocellular carcinoma: management with transheptic arterioembolization. Abdom Imaging 2000; 25:380.
  19. Hayward SR, Lucas CE, Ledgerwood AM. Recurrent spontaneous intrahepatic hemorrhage from peliosis hepatis. Arch Surg 1991; 126:782.
  20. Cooperman AM, Weiland LH, Welch JS. Massive bleeding from a ruptured metastatic hepatic melanoma treated by hepatic lobectomy. Case report and review of the literature. Mayo Clin Proc 1976; 51:167.
  21. Autry JR, Weitzner S. Hemangiosarcoma of spleen with spontaneous rupture. Cancer 1975; 35:534.
  22. Margolin KA, Pak HY, Esensten ML, Doroshow JH. Hepatic metastasis in granulosa cell tumor of the ovary. Cancer 1985; 56:691.
  24. Witz M, Bernheim J, Dinbar A, Griffel B. Kidney fibroxanthoma (malignant fibrous xanthoma): a rare tumor and an unusual cause of retroperitoneal hemorrhage. J Surg Oncol 1984; 26:146.
  25. Witz M, Shpitz B, Dinbar A. Massive intraabdominal bleeding due to a retroperitoneal leiomyosarcoma. J Surg Oncol 1983; 24:132.
  26. Nguyen HT, Wolf JS Jr, Nash PA, et al. Acute retroperitoneal hemorrhage due to transitional cell carcinoma of the renal pelvis. J Urol 1995; 153:140.
  27. Swift DL, Lingeman JE, Baum WC. Spontaneous retroperitoneal hemorrhage: a diagnostic challenge. J Urol 1980; 123:577.
  28. Graham E, Cohen AW, Soulen M, Faye R. Symptomatic liver hemangioma with intra-tumor hemorrhage treated by angiography and embolization during pregnancy. Obstet Gynecol 1993; 81:813.
  29. Okazaki M, Higashihara H, Koganemaru F, et al. Intraperitoneal hemorrhage from hepatocellular carcinoma: emergency chemoembolization or embolization. Radiology 1991; 180:647.
  30. Gaffey MJ, Frierson HF Jr, Medeiros LJ, Weiss LM. The relationship of Epstein-Barr virus to infection-related (sporadic) and familial hemophagocytic syndrome and secondary (lymphoma-related) hemophagocytosis: an in situ hybridization study. Hum Pathol 1993; 24:657.
  31. Aung W, Koslosky W, Chin NW, Pincus MR. Diffuse large cell lymphoma of B-cell type associated with reactive hemophagocytosis. Ann Clin Lab Sci 1996; 26:433.
  32. Kobayashi Y, Uehara S, Inamori K, et al. Hemophagocytosis as a para-neoplastic syndrome in NK cell leukemia. Int J Hematol 1996; 64:135.
  33. Imashuku S, Hibi S, Sako M, et al. Hemophagocytosis by leukemic blasts in 7 acute myeloid leukemia cases with t(16;21)(p11;q22): common morphologic characteristics for this type of leukemia. Cancer 2000; 88:1970.
  34. Tsoi WC, Feng CS. Hemophagocytosis by rhabdomyosarcoma cells in bone marrow. Am J Hematol 1997; 54:340.
  35. Molad Y, Stark P, Prokocimer M, et al. Hemophagocytosis by small cell lung carcinoma. Am J Hematol 1991; 36:154.
  36. Conlan MG, Armitage JO, Bast M, Weisenburger DD. Clinical significance of hematologic parameters in non-Hodgkin's lymphoma at diagnosis. Cancer 1991; 67:1389.
  37. Rubins JM. The role of myelofibrosis in malignant leukoerythroblastosis. Cancer 1983; 51:308.
  38. Delsol G, Guiu-Godfrin B, Guiu M, et al. Leukoerythroblastosis and cancer frequency, prognosis, and physiopathologic significance. Cancer 1979; 44:1009.
  39. O'Keane JC, Wolf BC, Neiman RS. The pathogenesis of splenic extramedullary hematopoiesis in metastatic carcinoma. Cancer 1989; 63:1539.
  40. Shamdas GJ, Ahmann FR, Matzner MB, Ritchie JM. Leukoerythroblastic anemia in metastatic prostate cancer. Clinical and prognostic significance in patients with hormone-refractory disease. Cancer 1993; 71:3594.
  41. Kavanaugh JH. Multiple myeloma, amyloid arthropathy, and pathological fracture of the femur: a case report. J Bone Joint Surg Am 1978; 60:135.
  42. Lanjewar DN, Raghuwanshi SR, Gupta D, et al. Systemic amyloidosis in Hodgkin's disease. Indian J Pathol Microbiol 1998; 41:169.
  43. Pérez Equiza E, Arguiñano JM, Gastearena J. Successful treatment of AA amyloidosis secondary to Hodgkin's disease with 4'-iodo-4'-deoxydoxorubicin. Haematologica 1999; 84:93.
  44. Simmonds PD, Cottrell BJ, Mead GM, et al. Lymphadenopathy due to amyloid deposition in non-Hodgkin's lymphoma. Ann Oncol 1997; 8:267.
  45. Gertz MA, Kyle RA, Noel P. Primary systemic amyloidosis: a rare complication of immunoglobulin M monoclonal gammopathies and Waldenström's macroglobulinemia. J Clin Oncol 1993; 11:914.
  46. Coakley FV, Hricak H, Presti JC Jr, Small EJ. Diffuse retroperitoneal amyloidosis due to renal cell carcinoma. Br J Radiol 1999; 72:412.
  47. Delgado MA, Liu JY, Meleg-Smith S. Systemic amyloidosis associated with hepatocellular carcinoma. Case report and literature review. J La State Med Soc 1999; 151:474.
  48. Terrier B, Jaccard A, Harousseau JL, et al. The clinical spectrum of IgM-related amyloidosis: a French nationwide retrospective study of 72 patients. Medicine (Baltimore) 2008; 87:99.
  49. Spira MA, Lynch EC. Autoimmune hemolytic anemia and carcinoma: an unusual association. Am J Med 1979; 67:753.
  50. Engelfriet CP, Overbeeke MA, von dem Borne AE. Autoimmune hemolytic anemia. Semin Hematol 1992; 29:3.
  51. Myint H, Copplestone JA, Orchard J, et al. Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Br J Haematol 1995; 91:341.
  52. Gonzalez H, Leblond V, Azar N, et al. Severe autoimmune hemolytic anemia in eight patients treated with fludarabine. Hematol Cell Ther 1998; 40:113.
  53. Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia. J Clin Oncol 1998; 16:1885.
  54. Juliusson G. Complications in the treatment of CLL with purine analogues. Hematol Cell Ther 1997; 39 Suppl 1:S41.
  55. Cohen JA, Brecher ME, Bandarenko N. Cellular source of serum lactate dehydrogenase elevation in patients with thrombotic thrombocytopenic purpura. J Clin Apher 1998; 13:16.
  56. Lin YC, Chang HK, Sun CF, Shih LY. Microangiopathic hemolytic anemia as an initial presentation of metastatic cancer of unknown primary origin. South Med J 1995; 88:683.
  57. Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999; 341:586.
  58. Rytting M, Worth L, Jaffe N. Hemolytic disorders associated with cancer. Hematol Oncol Clin North Am 1996; 10:365.
  59. Sheldon R, Slaughter D. A syndrome of microangiopathic hemolytic anemia, renal impairment, and pulmonary edema in chemotherapy-treated patients with adenocarcinoma. Cancer 1986; 58:1428.
  60. Laffay DL, Tubbs RR, Valenzuela R, et al. Chronic glomerular microangiopathy and metastatic carcinoma. Hum Pathol 1979; 10:433.
  61. Lockhart AC. Microangiopathic haemolytic anaemia in metastatic malignancy. Hosp Med 2001; 62:244.
  62. Contrino J, Hair G, Kreutzer DL, Rickles FR. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med 1996; 2:209.
  63. Zwicker JI, Furie BC, Furie B. Cancer-associated thrombosis. Crit Rev Oncol Hematol 2007; 62:126.
  64. Kasthuri RS, Taubman MB, Mackman N. Role of tissue factor in cancer. J Clin Oncol 2009; 27:4834.
  65. Conway EM, Rosenberg RD. Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Mol Cell Biol 1988; 8:5588.
  66. van der Poll T, Büller HR, ten Cate H, et al. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990; 322:1622.
  67. Menell JS, Cesarman GM, Jacovina AT, et al. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med 1999; 340:994.
  68. Feinstein DI. Diagnosis and management of disseminated intravascular coagulation: the role of heparin therapy. Blood 1982; 60:284.
  69. Groff JA, Kozak M, Boehmer JP, et al. Endotheliopathy: a continuum of hemolytic uremic syndrome due to mitomycin therapy. Am J Kidney Dis 1997; 29:280.
  70. Porta C, Danova M, Riccardi A, et al. Cancer chemotherapy-related thrombotic thrombocytopenic purpura: biological evidence of increased nitric oxide production. Mayo Clin Proc 1999; 74:570.
  71. Jackson AM, Rose BD, Graff LG, et al. Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy. Ann Intern Med 1984; 101:41.
  72. Fuge R, Bird JM, Fraser A, et al. The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation. Br J Haematol 2001; 113:58.
  73. van der Lelie H, Baars JW, Rodenhuis S, et al. Hemolytic uremic syndrome after high dose chemotherapy with autologous stem cell support. Cancer 1995; 76:2338.
  74. Bruntsch U, Groos G, Tigges FJ, Gallmeier WM. Microangiopathic hemolytic anemia, a frequent complication of mitomycin therapy in cancer patients. Eur J Cancer Clin Oncol 1984; 20:905.
  75. Means RT Jr, Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 1992; 80:1639.
  76. Means RT Jr. Advances in the anemia of chronic disease. Int J Hematol 1999; 70:7.
  77. Sharma S, Nemeth E, Chen YH, et al. Involvement of hepcidin in the anemia of multiple myeloma. Clin Cancer Res 2008; 14:3262.
  78. Hohaus S, Massini G, Giachelia M, et al. Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin. J Clin Oncol 2010; 28:2538.
  79. Falkensammer CE, Thurnher M, Leonhartsberger N, Ramoner R. C-reactive protein is a strong predictor for anaemia in renal cell carcinoma: role of IL-6 in overall survival. BJU Int 2011; 107:1893.
  80. Ciccarelli BT, Patterson CJ, Hunter ZR, et al. Hepcidin is produced by lymphoplasmacytic cells and is associated with anemia in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma Leuk 2011; 11:160.
  81. Demetri GD, Kris M, Wade J, et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998; 16:3412.
  82. JACOBS EM, HUTTER RV, POOL JL, LEY AB. Benign thymoma and selective erythroid aplasia of the bone marrow. Cancer 1959; 12:47.
  83. Hirst E, Robertson TI. The syndrome of thymoma and erythroblastopenic anemia. A review of 56 cases including 3 case reports. Medicine (Baltimore) 1967; 46:225.
  84. Dessypris EN. Pure Red Cell Aplasia, Johns Hopkins University Press, Baltimore 1988.
  85. Charles RJ, Sabo KM, Kidd PG, Abkowitz JL. The pathophysiology of pure red cell aplasia: implications for therapy. Blood 1996; 87:4831.
  86. Chikkappa G, Zarrabi MH, Tsan MF. Pure red-cell aplasia in patients with chronic lymphocytic leukemia. Medicine (Baltimore) 1986; 65:339.
  87. Lacy MQ, Kurtin PJ, Tefferi A. Pure red cell aplasia: association with large granular lymphocyte leukemia and the prognostic value of cytogenetic abnormalities. Blood 1996; 87:3000.
  88. Carloss HW, Saab GA, Tavassoli M. Pure red cell aplasia and lymphoma. JAMA 1979; 242:67.
  89. Krantz SB. Acquired pure red cell aplasia. In: Hematology: Basic Principles and Practice, 2nd ed, Hoffman R, Benz EJ, Shattil SJ, et al. (Eds), Churchill Livingstone, New York 1995. p.350.
  90. Krantz SB. Pure red-cell aplasia. N Engl J Med 1974; 291:345.
  91. Abkowitz JL, Kadin ME, Powell JS, Adamson JW. Pure red cell aplasia: lymphocyte inhibition of erythropoiesis. Br J Haematol 1986; 63:59.
  92. Taniguchi S, Shibuya T, Morioka E, et al. Demonstration of three distinct immunological disorders on erythropoiesis in a patient with pure red cell aplasia and autoimmune haemolytic anaemia associated with thymoma. Br J Haematol 1988; 68:473.
  93. Masuda M, Arai Y, Okamura T, Mizoguchi H. Pure red cell aplasia with thymona: evidence of T-cell clonal disorder. Am J Hematol 1997; 54:324.
  94. Yamada O, Yun-Hua W, Motoji T, Mizoguchi H. Clonal T-cell proliferation causing pure red cell aplasia in chronic B-cell lymphocytic leukaemia: successful treatment with cyclosporine following in vitro abrogation of erythroid colony-suppressing activity. Br J Haematol 1998; 101:335.
  95. Peschle C, Marmont AM, Marone G, et al. Pure red cell aplasia: studies on an IgG serum inhibitor neutralizing erythropoietin. Br J Haematol 1975; 30:411.
  96. Mangan KF, Chikkappa G, Scharfman WB, Desforges JF. Evidence for reduced erythroid burst (BFUE) promoting function of T lymphocytes in the pure red cell aplasia of chronic lymphocytic leukemia. Exp Hematol 1981; 9:489.
  97. Fujisao S, Tsuda H. Th1/Th2 balance alteration in the clinical course of a patient with pure red cell aplasia and thymoma. Br J Haematol 1998; 103:308.
  98. Penn CR, Hope-Stone HF. The role of radiotherapy in the management of malignant thymoma. Br J Surg 1972; 59:533.
  99. Gajwani B, Zinner EN. Pure red-cell aplasia. Associated with adenocarcinoma of stomach. N Y State J Med 1976; 76:2177.
  100. Zaentz SD, Krantz SB, Brown EB. Studies on pure red cell aplasia. Maintenance therapy with immunosuppressive drugs. Br J Haematol 1976; 32:47.
  101. Firkin FC, Maher D. Cytotoxic immunosuppressive drug treatment strategy in pure red cell aplasia. Eur J Haematol 1988; 41:212.
  102. Abkowitz JL, Powell JS, Nakamura JM, et al. Pure red cell aplasia: response to therapy with anti-thymocyte globulin. Am J Hematol 1986; 23:363.
  103. Kwong YL, Wong KF. Association of pure red cell aplasia with T large granular lymphocyte leukaemia. J Clin Pathol 1998; 51:672.
  104. Frickhofen N, Chen ZJ, Young NS, et al. Parvovirus B19 as a cause of acquired chronic pure red cell aplasia. Br J Haematol 1994; 87:818.
  105. Sharma VR, Fleming DR, Slone SP. Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab. Blood 2000; 96:1184.
  106. Kurtzman G, Frickhofen N, Kimball J, et al. Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med 1989; 321:519.
  107. Frickhofen N, Abkowitz JL, Safford M, et al. Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS. Ann Intern Med 1990; 113:926.
  108. McGuire WA, Yang HH, Bruno E, et al. Treatment of antibody-mediated pure red-cell aplasia with high-dose intravenous gamma globulin. N Engl J Med 1987; 317:1004.
  109. Clauvel JP, Vainchenker W, Herrera A, et al. Treatment of pure red cell aplasia by high dose intravenous immunoglobulins. Br J Haematol 1983; 55:380.
  110. Asbell SO, Leon SA, Tester WJ, et al. Development of anemia and recovery in prostate cancer patients treated with combined androgen blockade and radiotherapy. Prostate 1996; 29:243.
  111. Pedersen-Bjergaard J. Radiotherapy- and chemotherapy-induced myelodysplasia and acute myeloid leukemia. A review. Leuk Res 1992; 16:61.
  112. Cremin P, Flattery M, McCann SR, Daly PA. Myelodysplasia and acute myeloid leukaemia following adjuvant chemotherapy for breast cancer using mitoxantrone and methotrexate with or without mitomycin. Ann Oncol 1996; 7:745.
  113. Sobecks RM, Le Beau MM, Anastasi J, Williams SF. Myelodysplasia and acute leukemia following high-dose chemotherapy and autologous bone marrow or peripheral blood stem cell transplantation. Bone Marrow Transplant 1999; 23:1161.
  114. Wood PA, Hrushesky WJ. Cisplatin-associated anemia: an erythropoietin deficiency syndrome. J Clin Invest 1995; 95:1650.
  115. Doll DC, Weiss RB. Hemolytic anemia associated with antineoplastic agents. Cancer Treat Rep 1985; 69:777.
  116. Marani TM, Trich MB, Armstrong KS, et al. Carboplatin-induced immune hemolytic anemia. Transfusion 1996; 36:1016.
  117. Habibi B. Drug induced red blood cell autoantibodies co-developed with drug specific antibodies causing haemolytic anaemias. Br J Haematol 1985; 61:139.
  118. Noronha V, Burtness B, Murren J, Duffy TP. Oxaliplatin induces a delayed immune-mediated hemolytic anemia: a case report and review of the literature. Clin Colorectal Cancer 2005; 5:283.